myelofibrosis

(redirected from Idiopathic myelofibrosis)
Also found in: Dictionary, Thesaurus, Medical.
Related to Idiopathic myelofibrosis: primary myelofibrosis

myelofibrosis

[‚mī·ə·lō·fī′brō·səs]
(pathology)
Growth of white, fibrous connective tissue in the bone marrow.
References in periodicals archive ?
The World Health Organization (WHO) diagnostic criteria for PV, essential thrombocythemia (ET) and idiopathic myelofibrosis (IMF) were revised after the discovery of JAK2 mutations in 2008 (for example: JAK2 V617F and JAK2 exon 12 mutations in virtually all patients with PV.
A total of 93 subjects with classical myeloproliferative neoplasms were evaluated in the study, 33(35%) of them were polycythaemia vera, 36 (39%) were essential thrombocythaemia and 24 (26%) were having idiopathic myelofibrosis.
Ozsoylu about our recently published case report titled "Complex cytogenetic findings in the bone marrow of a chronic idiopathic myelofibrosis patient".
Idiopathic myelofibrosis that is seen in adults is an incurable disease without allogeneic stem cell transplantation (1,2).
These findings were compatible with idiopathic myelofibrosis.
The name Chronic Idiopathic Myelofibrosis was last used in the 2001 WHO classification, the disorder now referred to as Primary Myelofibrosis is extremely rare and there have been <50 cases reported till date.
Chronic idiopathic myelofibrosis (CIMF) is characterized by splenomegaly, myeloid metaplasia and reactive bone marrow fibrosis, and it has the highest karyotype aberration rate (1-3).
None of our cases showed osteosclerosis and there was absence of significant leukoerythroblastosis as opposed to cases idiopathic myelofibrosis.
As is evident from our cases (Table 3), the hematological features of AIMF described in the literature also show some overlapping and some distinct features from chronic idiopathic myelofibrosis (CIMF).
Lymphoid infiltrates and autoimmune phenomenon have been reported in idiopathic myelofibrosis [8-13].
Chronic Idiopathic Myelofibrosis Pipeline Review, Q4 2010, provides an overview of the Chronic Idiopathic Myelofibrosis therapeutic pipeline.
Full browser ?